Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis

References

• Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K, et al. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(1):31–40.
   PubMed Web of Science ®Google Scholar
• Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, et al. The first double-blind, randomized, parallel-group certolizumab pegol study in methotrexate-naïve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016;75(1):75–83.
   PubMed Web of Science ®Google Scholar
• Emery P, Horton S, Dumitru RB, Naraghi K, van der Heijde D, Wakefield RJ, et al. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. Ann Rheum Dis. 2020;79(4):464–71.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.
   PubMed Web of Science ®Google Scholar
• Kameda H, Amano K, Sekiguchi N, Takei H, Ogawa H, Nagasawa H, et al. Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients. Mod Rheumatol. 2004;14(6):442–6.
   PubMedGoogle Scholar
• Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010;69(7):1333–7.
   PubMed Web of Science ®Google Scholar
• Nishina N, Kaneko Y, Kameda H, Kuwana M, Takeuchi T. Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin Rheumatol. 2013;32(11):1661–6.
   PubMed Web of Science ®Google Scholar
• Cooper DL, Martin SG, Robinson JI, Mackie SL, Charles CJ, Nam J, et al. FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. PLoS One. 2012;7(1):e28918.
   PubMed Web of Science ®Google Scholar
• De Rotte MCFJ, Pluijm SMF, de Jong PHP, Bulatovic Calasan M, Wulffraat NM, Weel AEAM, et al. Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis. PLoS One. 2018;13(12):e0208534.
   PubMed Web of Science ®Google Scholar
• Sergeant JC, Hyrich KL, Anderson J, Kopec-Harding K, Hope HF, Symmons DPM, et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther. 2018;20(1):147.
   PubMedGoogle Scholar
• Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, et al. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical response. Ann Rheum Dis. 2018;77(9):1261–7.
   PubMed Web of Science ®Google Scholar
• Milic V, Jekic B, Lukovic L, Bunjevacki V, Milasin J, Novakovic I, et al. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(2):178–83.
   PubMed Web of Science ®Google Scholar
• Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997;89(3):1013–8.
   PubMed Web of Science ®Google Scholar
• Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem J. 2002;367(Pt 3):741–50.
   PubMedGoogle Scholar
• Kim JS, Lowe KE, Shane B. Regulation of folate and one-carbon metabolism in mammalian cells. IV. Role of folylpoly-gamma-glutamate synthetase in methotrexate metabolism and cytotoxicity. J Biol Chem. 1993;268(29):21680–5.
   PubMed Web of Science ®Google Scholar
• Hall MJ, Lawrence DA, Lansiedel JC, Walsh AC, Comstock LL, Kremer JM. Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in Jurkat T cells. Int J Immunopharmacol. 1998;19(11–12):709–20.
   Web of Science ®Google Scholar
• Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood.1995;85(2):500–9.
   PubMed Web of Science ®Google Scholar
• Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, et al. Molecular mechanisms of resistance to antifolates, a review. Acta Biochim Pol. 1995;42(4):457–64.
   PubMed Web of Science ®Google Scholar
• Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Stem Cells. 1996;14(1):5–9.
   PubMed Web of Science ®Google Scholar
• Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res. 1993;53(10 Suppl):2227–30.
   PubMed Web of Science ®Google Scholar
• Waltham MC, Li WW, Gritsman H, Tong WP, Bertino JR. gamma-Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists. Mol Pharmacol. 1997;51(5):825–32.
   PubMed Web of Science ®Google Scholar
• Kunishio K, Okada M, Matsumoto Y, Nagao S. Preliminary individual adjuvant chemotherapy for primary central nervous system lymphomas based on the expression of drug-resistance genes. Brain Tumor Pathol. 2004;21(2):57–61.
   PubMedGoogle Scholar
• Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 2002;62(17):5035–40.
   PubMed Web of Science ®Google Scholar
• van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC, Scheffer GL, et al. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum. 2009;60(3):669–77.
   PubMedGoogle Scholar
• Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003;63(14):4048–54.
   PubMed Web of Science ®Google Scholar
• Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003;63(17):5538–43.
   PubMed Web of Science ®Google Scholar
• Muto S, Iida K, Shinoda K, Saitoh M, Tsumura N, Shinohara E, et al. High expression of breast cancer resistance protein is correlated with the resistance to methotrexate in patients with rheumatoid arthritis. Pharmacometrics. 2015;88:31–8.
   Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CII, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
   PubMed Web of Science ®Google Scholar
• van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against rheumatism criteria. Arthritis Rheum. 1996;39(1):34–40.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
   PubMed Web of Science ®Google Scholar
• Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis. 2004;63(4):415–9.
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145–54.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Suzuki K, Iijima H, Hata Y, Lim CR, Ishizawa Y, et al. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. Arthritis Res Ther. 2016;18:159.
   PubMed Web of Science ®Google Scholar
• Isshiki M, Umezawa K, Tamura H. Coffee induces breast cancer resistance protein expression in Caco-2 cells. Biol Pharm Bull. 2011;34(10):1624–7.
   PubMed Web of Science ®Google Scholar
• Wang X, Wu X, Wang C, Zhang W, Ouyang Y, Yu Y, He Z. Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells. FEBS Lett. 2010;584(15):3392–7.
   PubMed Web of Science ®Google Scholar
• Mosaffa F, Lage H, Afshari JT, Behravan J. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res. 2009;58(10):669–76.
   PubMed Web of Science ®Google Scholar
• Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J Biol Chem. 2010;285(41):31100–6.
   PubMed Web of Science ®Google Scholar
• Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol. 2010;30(1):63–70.
   PubMed Web of Science ®Google Scholar
• Mosaffa F, Kalalinia F, Lage H, Afshari JT, Behravan J. Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells. Mol Cell Biochem. 2012;363(1–2):385–93.
   PubMed Web of Science ®Google Scholar
• Eektimmerman F, Swen JJ, Madhar MB, Allaart CF, Guchelaar HJ. Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review. Pharmacogenomics J. 2020;20(2):159–68.
   PubMed Web of Science ®Google Scholar
• Hakamata J, Kaneko Y, Shimizu M, Yamaoka K, Maruyama J, Takeuchi T, et al. Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis: a hospital-based cohort study. Biol Pharm Bull. 2018;41(9):1414–22.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shikano K, Nanki T, Kawai S. Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. Sci Rep. 2016;6:35615.
   PubMed Web of Science ®Google Scholar
• Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open. 2017;3(1):e000363.
   PubMed Web of Science ®Google Scholar